Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study

Fit for purpose: antiretroviral treatment optimisation Feb 2017

US Stribild label updated: new indication to include patients age 12 and older

Option to take crushed Stribild tablets with food or enteral nutrition

ART adherence in first four months predicts long-term viral suppression in 12-year study

Effects of ART initiation on human papillomavirus antibody response

Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses

Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients

Once-weekly albuvirtide infusion: early results of T-20-like compound

FDA approves maraviroc for children aged two and older

Ibalizumab infusion reduces viral load in people with HIV multi-drug resistance

GSK discontinues development of maturation inhibitor BMS-955176

Large disparities in costs of antiretrovirals between low- and middle-income countries

High death rates among HIV positive women postpartum accessing ARVs

Higher rates of eye complications in HIV positive people on ART

Raltegravir-based third-line ART in children and adolescents

Raltegravir in HIV-exposed neonates

Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s

First generic TDF/FTC approved in EU

Single-pill PI-based combination submitted to EMA

Dolutegravir superior to standard dose efavirenz in WHO analysis

Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study

Once-daily raltegravir at last available: 48 week results from ONCEMRK study

Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2

Dolutegravir is superior to boosted atazanavir in women in the ARIA study

Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery

The antiretroviral pipeline 2016

Fit for purpose: antiretroviral treatment optimisation 2016

The paediatric antiretroviral pipeline

Preventive technologies: antiretroviral and vaccine development

HIV positive people on ART have impaired alveolar immunity

Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries

No effect of tenofovir on infant bone mineral content in African study

Use of modelling to predicting paediatric dosing of long acting antiretrovirals

START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers

FTC/TAF dual-nuke approved in the US and Europe

Paediatric labeling expanded, and additional tablet strengths for FTC/TDF

Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study

New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP

Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART

48-week results for NNRTI doravirine compared to efavirenz

Countries with lower HIV prevalence have lower ART coverage

Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals

EU adopts positive opinion on dual formulation of F/TAF

New TAF-containing fixed dose combination approved in the US

BMS sells pipeline compounds to ViiV Healthcare

EU provide positive approval for generic lopinavir/ritonavir

Further results using dolutegravir monotherapy: urgent need for controlled studies

Potential economic impact of dolutegravir/3TC dual therapy

Remarkable results with dolutegravir monotherapy

First-line ART with dolutegravir plus 3TC: 24-week early results

Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

Substituting lopinavir/ritonavir with efavirenz in children on stable ART

Tenofovir alafenamide (TAF) approved – but only as part of a fixed dose combination

No transmission of integrase-resistant HIV seen in California cohort

Doubled hypogonadism rate in middle-aged men with HIV: fat is a factor

Reducing efavirenz dose is unlikely to overcome interaction with levonorgestrel

Doravirine and cabotegravir do not affect the pharmacokinetics of oral contraceptives

Dolutegravir placental transfer moderate in ex vivo model

FDA approve additional weight band dosing for children using atazanavir powder

Four reasons IAS 2015 will be a milestone HIV conference: a personal view

Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study

Pipeline ARVs at IAS 2015: doravirine, BMS-955176 and BMS-663068

Rapid implementation of the 2013 WHO ART guidelines

Rilpivirine/FTC/TAF becomes the third TAF-based fixed dose combination submitted for US approval

Post navigation